Helsinn demonstrates commitment to MF CTCL with multiple scientific sessions at the EORTC Cutaneous Lymphoma Meeting 2019
September 26, 2019 08:54 ET
|
Helsinn Healthcare S.A.
Helsinn demonstrates commitment to MF CTCL with multiple scientific sessions at the EORTC Cutaneous Lymphoma Meeting 2019 Lugano, Switzerland, September 26, 2019 – Helsinn, the Swiss pharmaceutical...
Helsinn announces abstract accepted for oral presentation at the EORTC Cutaneous Lymphoma Meeting 2019
September 26, 2019 06:35 ET
|
Helsinn Healthcare S.A.
Helsinn announces abstract accepted for oral presentation at the EORTC Cutaneous Lymphoma Meeting 2019 Lugano, Switzerland, September 26, 2019 – Helsinn, the Swiss pharmaceutical group focused on...
Helsinn and Recordati Rare Diseases to announce satellite symposium on advances in Mycosis Fungoides-Cutaneous T cell Lymphoma
September 19, 2019 04:00 ET
|
Helsinn Healthcare S.A.
Helsinn and Recordati Rare Diseases to announce satellite symposium on advances in Mycosis Fungoides-Cutaneous T cell Lymphoma (MF-CTCL) treatment at the 49th European Society for Dermatological...
Helsinn signs exclusive distribution and license agreements with Blanver and Varifarma for Pracinostat in South America
September 02, 2019 08:30 ET
|
Consilium Strategic Communications
Helsinn signs exclusive distribution and license agreements with Blanver and Varifarma for Pracinostat in South America Lugano, Switzerland, São Paulo, Brazil, and Buenos Aires,...
Helsinn and Endo Announce Agreement for Paladin Labs Inc. to Commercialize Pracinostat in Canada
July 31, 2019 08:10 ET
|
Helsinn Healthcare S.A.
Helsinn and Endo Announce Agreement for Paladin Labs Inc. to Commercialize Pracinostat in Canada DUBLIN and LUGANO, July 31, 2019 -- Endo International plc (NASDAQ: ENDP), and Helsinn, a Swiss...
Helsinn appoints Giorgio Calderari, Group General Manager and Chief Operating Officer, to the Board of Directors
June 26, 2019 01:00 ET
|
Helsinn Healthcare S.A.
Helsinn appoints Giorgio Calderari, Group General Manager and Chief Operating Officer, to the Board of Directors Lugano, Switzerland, June 26, 2019: Helsinn, the Swiss pharmaceutical group focused on...
Helsinn Group supports two events with the International Society for Cutaneous Lymphomas (ISCL) at the 24th World Congress of Dermatology
June 07, 2019 03:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group supports two events with the International Society for Cutaneous Lymphomas (ISCL) at the 24th World Congress of Dermatology Cutaneous Lymphoma Meeting will update on latest developments...
Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Dr. Allison Barz Leahy, MD, University of Pennsylvania
June 01, 2019 08:00 ET
|
Helsinn Healthcare S.A.
Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Dr. Allison Barz Leahy, MD, University of Pennsylvania ...
Winners of the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced
March 19, 2019 18:00 ET
|
Helsinn Healthcare S.A.
Winners of the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced Mihir Shah of UE LifeSciences Inc. has been selected as the winner of the 2019 Lyfebulb-Helsinn...
Helsinn initiates two new global Phase III studies with anamorelin
March 07, 2019 03:00 ET
|
Helsinn Healthcare S.A.
Helsinn initiates two new global Phase III studies with anamorelin Helsinn committed to anamorelin which is being evaluated for weight loss and anorexia in patients with advanced non small cell lung...